Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:TP53_mutation
|
| gptkbp:affects |
DNA binding
|
| gptkbp:associated_with |
gptkb:Oncology
|
| gptkbp:can_lead_to |
tumorigenesis
|
| gptkbp:cause |
loss of function
|
| gptkbp:community |
cell cycle regulation
|
| gptkbp:disrupts |
p53 protein function
|
| https://www.w3.org/2000/01/rdf-schema#label |
TP53 R273 H
|
| gptkbp:increased |
cell proliferation
|
| gptkbp:investigates |
pharmacogenomics
biological therapies molecular mechanisms |
| gptkbp:is_a |
missense mutation
|
| gptkbp:is_analyzed_in |
biomarker studies
|
| gptkbp:is_associated_with |
disease progression
survival rates tumor microenvironment clinical outcomes metastasis poor prognosis immune evasion treatment resistance |
| gptkbp:is_characterized_by |
mutation analysis
gain of function altered protein structure arginine to histidine substitution mutation hotspot |
| gptkbp:is_common_in |
high-grade tumors
|
| gptkbp:is_examined_in |
clinical trials
genetic studies therapeutic strategies genetic counseling molecular genetics molecular profiling |
| gptkbp:is_found_in |
gptkb:Human
|
| gptkbp:is_involved_in |
cellular stress response
|
| gptkbp:is_linked_to |
cellular differentiation
inflammatory response cellular signaling pathways tumor progression chemoresistance cellular apoptosis |
| gptkbp:is_part_of |
cancer research initiatives
cancer genomics cancer diagnostics cancer pathways TP53 gene alterations |
| gptkbp:is_recognized_by |
liquid biopsies
tumor samples |
| gptkbp:is_related_to |
genomic instability
|
| gptkbp:is_studied_for |
risk assessment
therapeutic targets |
| gptkbp:is_studied_in |
clinical research
pathology reports oncology research. |
| gptkbp:is_tested_for |
targeted therapy
|
| gptkbp:is_utilized_in |
personalized medicine
|
| gptkbp:occurs_in |
gptkb:Oncology
|
| gptkbp:reduces |
apoptosis
|
| gptkbp:reported_by |
gptkb:literature
|
| gptkbp:resulted_in |
altered transcriptional activity
|
| gptkbp:bfsParent |
gptkb:TP53
|
| gptkbp:bfsLayer |
5
|